Perspective Confidentiality Disclosure Reliability Courtesy
Between the general exhaustion of the urology community after the AUA and the Memorial Day “long weekend” here in the USA, it’s likely to be pretty quiet on the prostate cancer front for at least a couple of days. Don’t be surprised if there’s little to report before Tuesday, May 27. … And don’t worry, [...]
Filed under: Uncategorized | No Comments »
There is a report in today’s Washington Post about a Phase I trial of a “vaccine” (please read “immunotherapeutic agent”) that might, just possibly (five or six years from now) be shown to have efficacy in the treatment of prostate cancer. However, the critical part of the article doesn’t appear until paragraphs 11 and 12, so [...]
Filed under: Management, Treatment | 5 Comments »
Yesterday appears to have been a more productive day from the viewpoint of the prostate cancer patient, although, once again, the occasional conclusion drawn by presenters would seem to reflect their hopes as opposed to the facts.
Filed under: Diagnosis, Management, Treatment | 3 Comments »
Once again there was a vast amount of information available from the AUA’s annual meeting in Orlando yesterday. However, much of that information offers relatively little in terms of practical knowledge for the newly diagnosed patient or prostate cancer survivors. We have provided examples of some of these studies, with commentary.
Filed under: Diagnosis, Management, Treatment | No Comments »
There were numerous presentations at yesterday’s AUA sessions related to prostate cancer. We have identified six presentations of general significance to risk for prostate cancer in general and newly diagnosed patients.
Filed under: Diagnosis, Management, Treatment | No Comments »
The “New” Prostate Can InfoLink does not believe that recently published data necessarily implies that prostate biopsy is associated with increased risk of death at 120 days. However, the data presented in a paper just published does suggest that a careful analysis of this risk may be important.
Filed under: Uncategorized | No Comments »
These updates will focus on newly available data presented at the annual meeting of the American Urological Association that offer important new or expanded knowledge for patients. We do not intend to cover every piece of new science presented at the meeting.
On Sunday, May 18, the following key pieces of knowledge were presented for the [...]
Filed under: Diagnosis, Management, Treatment | No Comments »
It appears that extending the amount of time over which radiotherapy (RT) is given to patients in treatment of localized prostate cancer may increase the risk for biochemical failure in a subset of those patients — the ones already at low risk for rapidly progressive disease. Patients at low risk for progressive prostate cancer who [...]
Filed under: Uncategorized | No Comments »
According to an abstract of a presentation to be given at the American Society of Clincial Oncology (ASCO) annual meeting in a couple of weeks, Amgen Inc.’s experimental drug denosumab was more effective than zoledronate (Zometa) in preventing fractures in cancer patients — at least in early test results.
Filed under: Uncategorized | No Comments »
An article just published in the online version of Cancer suggests that:
While many men are appropriate candidates for active surveillance (AS), in 2006 only about 10 percent of those eligible actually chose it (up from about 6 percent in 2000), and furthermore
Of those that do initially choose AS, up to 50 percent will convert to [...]
Filed under: Diagnosis, Management, Treatment | 1 Comment »
